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Abstract Over 40% of breast cancer patients are diag-
nosed above the age of 65. Treatment of these elderly
patients will probably vary over countries. The aim of this
study was to make an international comparison (several
European countries and the US) of surgical and radiation
treatment for elderly women with early stage breast cancer.
Survival comparisons were also made. Data were obtained
from national or regional population-based registries in the
Netherlands, Switzerland, Ireland, Belgium, Germany, and
Portugal. For the US patients were selected from the Sur-
veillance, Epidemiology, and End Results (SEER) data-
base. Early stage breast cancer patients aged C65
diagnosed between 1995 and 2005 were included. An
international comparison was made for breast and axillary
surgery, radiotherapy after breast conserving surgery
(BCS), and relative or cause-speciﬁc survival. Overall,
204.885 patients were included. The proportion of patients
not receiving any surgery increased with age in many
countries; however, differences between countries were
large. In most countries more than half of all elderly
patients received breast conserving surgery (BCS), with the
highest percentage in Switzerland. The proportion of
elderly patients that received radiotherapy after BCS
decreased with age in all countries. Moreover, in all
countries the proportion of patients who do not receive
axillary surgery increased with age. No large differences in
survival between countries were recorded. International
comparisons of surgical treatment for elderly women with
early stage breast cancer are scarce. This study showed
large international differences in treatment of elderly early
stage breast cancer patients, with the most striking result
the large proportion of elderly who did not undergo surgery
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Introduction
Breast cancer is the most frequently diagnosed cancer
worldwide, accounting for 23% of all new cancer cases in
women and 14% of all female cancer deaths in 2008 [1]. A
high incidence of breast cancer is observed in women aged
65 years and older, comprising over 40% of all breast
cancer patients in developed countries [2]. Given the aging
population and constantly improving screening and diag-
nostic tools, the number of elderly patients with breast
cancer is expected to grow in the coming decades [3].
Clinical trials indicate that the choice of mastectomy
versus breast conserving surgery (BCS) followed by
radiotherapy (RT) for early stage breast cancer does not
affect overall mortality or breast cancer mortality [4, 5].
However, patients who receive BCS ? RT have a small
but signiﬁcant increase in local recurrences. Elderly
patients have been under-represented in breast cancer
treatment trials, based on their age, comorbid diseases, and
logistic barriers [2, 6]. Consequently it is questionable if
trial results can be generalized to patients of all ages.
Despite guideline recommendations, several observational
studies from different countries show that with increasing
age, treatment of early stage breast cancer more often
consists of mastectomy; moreover, omission of RT after
BCS increases with increasing age [3, 7–11]. In addition,
older breast cancer patients are more likely than younger
patients to not undergo breast surgery, even though mor-
tality caused by breast surgery is shown to be low among
elderly [12].
The different treatment approaches to elderly breast
cancer patients could have consequences. Several obser-
vational studies showed worse overall, breast cancer spe-
ciﬁc, and disease-free survival for ‘undertreated’ elderly
patients (not treated according to guidelines) [13, 14]. An
international study comparing breast surgery among
countries for patients participating in the Tamoxifen exe-
mestane adjuvant multinational (TEAM) trial showed large
differences in surgical treatment approach to early stage
breast cancer in postmenopausal women [15]. The EU-
ROCARE group recently published a population-based
study on the surgical treatment of early stage breast cancer
(T1N0M0) across Europe. They found considerable dif-
ferences in the use of BCS followed by RT. Of all surgi-
cally treated patients across the participating countries,
55% received BCS ? RT, with a range from 9% in Estonia
to 78% in France [11]. However, none of these studies
speciﬁcally compared treatment of the elderly patient with
breast cancer. The aim of this study is to make an inter-
national comparison of breast and axillary surgery, and
radiotherapy after breast conserving surgery in elderly
patients with early stage breast cancer, and its possible
inﬂuence on survival.
Methods
Patients
Women aged 65 and older, who were diagnosed with early
stage breast cancer (T0-2, N0-1, M0) and recorded in
population-based cancer registries in the Netherlands, Ire-
land, Switzerland, Belgium, Germany, Portugal, and the
U.S. were included. From the population-based database of
the Netherlands Cancer Registry, women diagnosed
between 1995 and 2005 were selected. For the US, patients
diagnosed between 1998 and 2007 were selected from the
Surveillance, Epidemiology, and End Results (SEER)
database covering 28% of the US population. In Switzer-
land, patients diagnosed between 2003 and 2005 were
identiﬁed from seven population-based cancer registries
(Geneva, Valais, Ticino, St Gallen-Appenzell, Grisons-
Glarus, Basel city and countryside, and Zurich) covering
47% of the Swiss population. In Ireland, patients were
selected from the national cancer registry between 1999
and 2007. In Belgium, patients diagnosed between 2001
and 2006 were selected from the national cancer registry.
German patients diagnosed between 1995 and 2008 in the
Munich region were selected. Finally, patients from the
Portugal South regional cancer registry (ROR-Sul) were
selected between 2006 and 2008. Patients with a diagnosis
of breast cancer on death certiﬁcate or at autopsy only or
with unknown treatment were excluded.
Statistics
Calculations of treatment percentages and survival were
performed for each country and aggregated into tables for
the comparison between countries. Patients were catego-
rized in six age groups (65–69, 70–74, 75–79, 80–84,
85–89, and C90) for the treatment analyses. Tumor stage
was deﬁned by combined TNM stage [16] (categorized as
stage I, IIA, IIB), with clinical stage used when patholog-
ical stage was missing. Stage I includes T1N0 tumors,
stage IIA T1N1, or T2N0 tumors and stage IIB contains
T2N1 tumors (also T3N0 tumors but these were excluded
from this study). Breast surgery was categorized as mas-
tectomy, breast conserving surgery, or no surgery. Patients
who received BCS ﬁrst, but later received mastectomy,
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123for any reason, were positioned in the mastectomy group.
Receipt of radiation in addition to BCS was also assessed.
Axillary surgery (either sentinel node biopsy or axillary
lymph node sampling or dissection) was documented (yes/
no). Descriptive statistics were used, as only aggregated
tables were compared, to assess the proportion of patients
receiving each treatment; where possible percentages were
compared using the v
2 test. A P value of\0.05 was con-
sidered statistically signiﬁcant.
Relative survival was calculated by the Ederer II method
as the ratio of the survival observed among the cancer
patients to the survival that would have been expected
based on the corresponding (age, sex, and year of diag-
nosis) general population. National life tables for each
country were used to estimate expected survival. In all
countries and regions, vital status was established either
directly from the patient’s medical record or through
linkage with the municipal or national population regis-
tries. The SEER database links with the National Death
index, which also provided causes of death, and disease-
speciﬁc survival was calculated for patients treated in the
US. Survival of Irish patients was mainly based on linkage
to national mortality data, sometime supplemented with
clinical information on date of death. For the survival
analysis age was categorized as 65–74, 75–84, and C85.
Results
Overall, 204.885 patients were included in the study.
Characteristics of the populations are shown in Table 1.
Age distribution was similar (P = 0.9) across participating
countries. Stage distribution among European countries
was comparable (P = 0.5), however, US patients more
frequently had stage I disease (P = 0.06). Grade distribu-
tion was signiﬁcantly different between the countries
(P\0.001).
Breast surgery
Figure 1 shows the proportions of patients who did not
receive breast surgery in the several countries by age. The
proportion of women not undergoing breast surgery varies
among countries (P\0.001) from 0.5% (MCR Germany)
to 13.4% (Ireland). Overall, the proportion of patients who
did not receive surgery increased with age. In the lowest
age categories (65–69 and 70–74), proportions of patients
without breast surgery were small (\5%) in all countries
(difference between countries were small but signiﬁcant
P\0.001). As age increases, larger differences in the
omission of breast surgery become apparent (again
P\0.001). In the US and Germany, in particular,
Table 1 Characteristics of the populations by country
Country Netherlands Belgium Switzerland Germany (MCR) Ireland Portugal
(ROR-Sul)
USA P value
Cases % Cases % Cases % Cases % Cases % Cases % Cases %
Age
65–69 10,162 28.6 2,337 33.1 465 32.1 4,539 39.3 1,295 30.0 40 32.3 36,629 25.3 0.9
70–74 9,636 27.1 1,818 25.8 365 25.2 3,077 26.7 1,142 26.5 40 32.3 35,109 24.2
75–79 6,982 19.6 1,503 21.3 273 18.8 2,322 20.1 901 20.9 23 18.5 33,279 23.0
80–84 5,260 14.8 907 12.9 171 12.0 1,152 10.0 631 14.6 13 10.5 23,592 16.3
85–89 2,687 7.6 340 4.8 100 7.2 376 3.3 271 6.3 7 5.6 11,678 8.1
90? 853 2.4 153 2.2 50 3.5 73 0.6 72 1.7 1 0.8 4,561 3.1
Stage
I 15,894 44.7 3,331 47.2 657 46.0 5,471 47.4 1,476 34.2 55 44.4 90,402 62.4 0.06
a
IIA 13,288 37.3 3,028 42.9 530 37.2 4,120 35.7 1,867 43.3 47 37.9 39,109 27.0
IIB
b 6,398 18.0 699 9.9 237 16.6 1,948 16.9 969 22.5 22 17.7 15,337 10.6
Grade
1 5,316 14.9 1,193 16.9 314 22.0 1,503 13.0 476 11.0 17 13.7 36,182 25.0 \0.001
2 12,036 33.8 2,983 42.3 794 55.8 6,888 59.7 1,890 43.8 81 65.3 61,178 42.2
3/4 7,383 20.8 2,259 32.0 253 17.7 2,842 24.6 1,188 27.6 11 8.9 35,409 24.5
Missing 10,845 30.5 623 8.8 63 4.4 306 2.7 758 17.6 15 12.1 12,079 8.3
Total 35,580 100 7,058 100 1424 100 11,539 100 4,312 100 124 100 144,848 100
MCR Munich cancer registry, ROR-Sul Portugal South Regional Cancer Registry
a P = 0.06 including US, but P = 0.5 among European countries only
b But excluding T3N0M0
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123relatively few patients did not undergo breast surgery.
However, in Ireland and the Netherlands more than half of
patients aged 90 years and older had no breast surgery.
Figure 2 shows the proportion of the patients that
received BCS (of all operated patients) in the countries by
age. In most countries more than half of the included
patients underwent BCS, except for the Netherlands, Ire-
land, and Portugal. The use of breast conserving procedures
was highest in Switzerland (70%). In all countries, except
for the US and Ireland, the proportion of BCS decreased
with age. In the US the proportion of BCS was relatively
stable with age and in Ireland the use of BCS increased
with age.
Radiotherapy after breast conserving surgery
Figure 3 shows the proportion of patients treated with BCS
who received adjuvant RT. This proportion decreased
substantially with age in all countries (P\0.001), and also
varied markedly between countries (P = 0.0005). The
largest overall proportion of BCS followed by RT was
observed in Belgium (85%) and the lowest in Portugal
(59%) although the sample size was small for the latter.
Axillary surgery
Figure 4 shows proportions of all included patients who did
not receive axillary surgery. The national cancer registry of
Belgium could not provide this information and in the US,
data on axillary staging were missing for 9.8% of patients.
In all countries, the percentage of patients who did not
undergo axillary surgery increased with age. However,
there was major variation among countries (P\0.001),
from 1.4% (MCR Germany) to 22.6% (Ireland) overall.
Survival
Figure 5 shows the 5-year survival after diagnosis by age
and stage. For all ages combined, there were no major
differences in survival between countries, with the highest
relative survival for Ireland (99%). Among stage I
patients, survival was similar between countries in all age
categories. For stage II, patients aged 65–74 years had a
similar survival in all countries, but there were differences
for patients aged 75–84 and patients aged C85, where
survival was higher for patients in Germany (MCR) and
Ireland.
*Less than 50 patients in the selection  
Fig. 1 Overall and age-speciﬁc
percentages of the patients who
did not receive breast surgery,
by country
%
*Less than 50 patients in the selection  
Fig. 2 Overall and age-speciﬁc
percentage of patients that
received breast conserving
surgery (of all patients that
received surgery), by country
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Major ﬁndings of this study were the large differences in
locoregional treatment across countries, especially in the
proportion of elderly breast cancer patients receiving no
breast surgery at all. However, despite substantial differ-
ences in breast cancer treatment, survival among countries
was comparable. International comparisons of surgical
treatment for elderly women with early stage breast cancer
are scarce. In this study, we were able to make a com-
parison between several European countries and the US.
Breast surgery
The international differences in the percentage of elderly
early stage breast cancer patients who did not undergo
breast surgery are striking. Whereas, for example, in Ire-
land the percentage of patients aged C90 who did not have
%
*Less than 50 patients in the selection  
Fig. 3 Overall and age-speciﬁc
percentages of patients that
received BCS with radiotherapy
(of all patients that received
BCS), by country
*Less than 50 patients in the selection  
**Missing 9.8% 
Fig. 4 Overall and age-speciﬁc
percentages of patients that
received no axillary surgery, by
country
*Disease-specific survival for the US 
Fig. 5 Relative survival (5-
years) for Stages I and II
disease, by age and country
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123surgery was 67%, in the US only 8.8% had no surgery and
in Germany all patients in this age category received breast
surgery. The ﬁndings in the US are consistent with a
recently published study from the US in which 98% of all
T1 or T2 breast cancer patients aged C65 years received at
least some surgery [17]. International studies comparing
the percentage of breast cancer patients who do not receive
surgery are scarce. Most observational studies of survival
excluded patients who did not have any surgical treatment,
but the few retrospective studies that did include non-sur-
gically treated patients showed poor overall and lower
breast cancer-speciﬁc survival for these patients [13, 17–
19]. Many descriptive studies from different countries have
also showed less extensive surgical treatment for elderly
women with early stage breast cancer compared with
younger patients [2, 3, 7, 11, 12].
Radiotherapy
An overview of clinical trial data has shown that BCS
should be followed by radiotherapy to achieve results
comparable with mastectomy in terms of recurrence and
survival [4]. In some elderly women BCS without radiation
may be used to minimize potential treatment-related
complications. However, the value of RT after BCS in
elderly breast cancer patients is still subject of debate, since
some studies suggest that radiation may be safely omitted
for low-risk tumors in women over age 70 [20, 21]. This
study shows that the proportion of women who received
RT after BCS decreased with age. This trend was found in
all participating countries, although speciﬁc proportions
vary. Notable are the high percentages of elderly patients
that received RT after BCS in Switzerland (79%) and
Germany (MCR 80%). Possibly, for Switzerland, high
accessibility of health services could partly explain this
ﬁnding. For the selected German region (Munich), a pre-
vious study demonstrated that this speciﬁc region has a
higher percentage of BCS for early stage breast cancer than
ﬁve other regions in Germany, so this region may not be
completely representative for the whole country [22]. Also
interesting are the differences in breast surgery between the
Netherlands and Ireland (both national databases). Both
countries have a high proportion of patients that receive no
breast surgery although it is higher in Ireland. The pro-
portion of BCS decreases with age in the Netherlands but
increases in Ireland; the proportion of adjuvant RT
decreases with age in both countries. This remarkable
difference in loco-regional therapy did not inﬂuence sur-
vival in any way. Information concerning loco-regional
recurrences, not routinely collected by most cancer regis-
tries, could add some information to these comparisons and
should be collected when possible in the future.
Axillary surgery
In all participating countries the proportion of women in
whom axillary surgery was not performed increased with
age, a ﬁnding consistent with another observational study
[23]. The largest proportion was found in Ireland, directly
followed by the US, Portugal and the Netherlands. Ger-
many stands out on this topic; only 1.4% of the elderly
breast cancer patients did not undergo any form of axillary
surgery. Axillary staging is part of some guidelines, and
these ﬁndings suggest that guideline adherence decreased
with increasing age. However, several randomized and
non-randomized studies showed very low rates of axillary
recurrences and comparable disease-free and overall sur-
vival between clinical node-negative elderly breast cancer
patients with and without axillary surgery [24, 25].
Strengths and limitations
One of the strengths of this comparison is the large number
of patients and the population-based datasets that included
all elderly patients. This facilitated comparison of treat-
ment strategies in countries with similar health systems by
using country as an instrumental variable.
A limitation of this study is that systemic treatment
information was not available for all countries. However,
available data indicate that rates of hormonal therapy (HT)
were high: for example, among non-surgically treated
patients, the proportion receiving HT was 85% in the
Netherlands and 69% in Ireland. However, it is question-
able if HT can replace surgery in elderly patients. Trials in
which women aged C70 were randomized to have surgery
or HT do not show signiﬁcant better overall survival for
surgery compared to HT alone, although risk of recurrence
is signiﬁcantly larger when operable breast cancer in
elderly is treated by tamoxifen alone [26, 27]. Another
limitation of this study might be that information con-
cerning the extent of ‘‘clear margins’’ after BCS was not
available.
Another limitation of the study could be differences in
data collection between the participating registries and the
absence of national data for several countries (only the
Netherlands, Belgium, and Ireland are national cancer
registries). In countries with regional data, the regions may
not be perfectly representative of the whole country. Also
the small number of patients included for Portugal may not
be representative and in some categories, numbers were
insufﬁcient to draw conclusions about treatment. Finally,
the years of available data were not completely overlap-
ping, and thus changes in treatment patterns over time
could inﬂuence our ﬁndings.
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123Conclusions
Despite the remarkable large differences in loco-regional
treatment of early breast cancer, this study showed minimal
differences in survival at 5 years between older breast
cancer patients from seven Western countries. These
ﬁndings raise the question whether more or less aggressive
treatment of early stage breast cancer in elderly makes a
difference. Future research should be focused on the best
therapy for elderly women with respect to survival and
quality of life. It may well be that the much criticized ‘‘less
aggressive therapy’’ for elderly breast cancer patients does
not harm patients with early stage disease, particularly
women with comorbid illness that may otherwise limit
their life expectancy. To properly investigate this, ran-
domized controlled trials, speciﬁcally aimed at the elderly,
is considered to give the best evidence. RCT’s, however,
are costly and time consuming en will not yield practice
changing results within years from the start of such a trial.
Furthermore, older patients are underrepresented in trials
and no direct comparison of different approaches to the
local regional treatment of early breast cancer in older
women is available. International comparison of speciﬁc
treatment protocols could serve as a good alternative to
select ‘best practices’ and improve the risk/beneﬁt ratio in
the treatment of older breast cancer patients. This com-
parative effectiveness research can bridge the knowledge
gap speciﬁcally in older cancer patient, who are by nature,
heterogeneous in patient characteristics and treatment
patterns [28].
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